Adamantane Resistance Among Influenza A Viruses Isolated Early During the 2005-2006 Influenza Season in the United States
CONTEXT The adamantanes, amantadine and rimantadine, have been used as first-choice antiviral drugs against community outbreaks of influenza A viruses for many years. Rates of viruses resistant to these drugs have been increasing globally. Rapid surveillance for the emergence and spread of resistant...
Gespeichert in:
| Veröffentlicht in: | JAMA : the journal of the American Medical Association 2006-02, Vol.295 (8), p.891-894 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 894 |
|---|---|
| container_issue | 8 |
| container_start_page | 891 |
| container_title | JAMA : the journal of the American Medical Association |
| container_volume | 295 |
| creator | Bright, Rick A Shay, David K Shu, Bo Cox, Nancy J Klimov, Alexander I |
| description | CONTEXT The adamantanes, amantadine and rimantadine, have been used as first-choice
antiviral drugs against community outbreaks of influenza A viruses for many
years. Rates of viruses resistant to these drugs have been increasing globally.
Rapid surveillance for the emergence and spread of resistant viruses has become
critical for appropriate treatment of patients. OBJECTIVE To investigate the frequency of adamantane-resistant influenza A viruses
circulating in the United States during the initial months of the 2005-2006
influenza season. DESIGN AND SETTING Influenza isolates collected from 26 states from October 1 through December
31, 2005, and submitted to the US Centers for Disease Control and Prevention
were tested for drug resistance as part of ongoing surveillance. Isolates
were submitted from World Health Organization collaborating laboratories and
National Respiratory and Enteric Virus Surveillance System laboratories. MAIN OUTCOME MEASURES Using pyrosequencing and confirmatory assays, we identified viruses
containing mutations within the M2 gene that are known to confer resistance
to both amantadine and rimantadine. RESULTS A total of 209 influenza A(H3N2) viruses isolated from patients in 26
states were screened, of which 193 (92.3%) contained a change at amino acid
31 (serine to asparagine [S31N]) in the M2 gene known to be correlated with
adamantane resistance. Two of 8 influenza A(H1N1) viruses contained the same
mutation. Drug-resistant viruses were distributed across the United States. CONCLUSIONS The high proportion of influenza A viruses currently circulating in
the United States demonstrating adamantane resistance highlights the clinical
importance of rapid surveillance for antiviral resistance. Our results indicate
that these drugs should not be used for the treatment or prophylaxis of influenza
in the United States until susceptibility to adamantanes has been reestablished
among circulating influenza A isolates.Published online February 2, 2006 (doi:10.1001/jama.295.8.joc60020). |
| doi_str_mv | 10.1001/jama.295.8.joc60020 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_67686490</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><ama_id>202422</ama_id><sourcerecordid>994463541</sourcerecordid><originalsourceid>FETCH-LOGICAL-a410t-78954027102cfa35b1e71bc94d44ea7c1ffb42877ee6cb48f36456ff4e75513c3</originalsourceid><addsrcrecordid>eNqFkVtr3DAQhUVIaDaXH1AKQRTSN29GN0t-XNKkWQgEcns1snbUerHlxLIfNr8-2uw2LXmJHkYCfXOGc4aQbwymDICdLW1rp7xQUzNddi4H4LBDJkwJkwlVmF0yAShMpqWR--QgxiWkw4T-QvZZLlUORk_IarZIMmGwAektxjqml0M6a7vwm86Db0YML5bO6GPdjxEjnceusQMu6IXtmxX9OfZ1Ioc_SDmAylLJ_-u7Qxu7QOvwRjyEet15NySBeET2vG0iHm_vQ_JweXF_fpVd3_yan8-uMysZDJk2hZLANQPuvBWqYqhZ5Qq5kBKtdsz7SnKjNWLuKmm8WHvzXqJWigknDsmPje5T3z2PGIeyraPDpkmWuzGWuc5NLgv4FGQ6JcZBJPD7B3DZjX1IJkrOmDBQwFrtZAuNVYuL8qmvW9uvyr_RJ-B0C9jobOP7FHwd_3FaAdtM-7rh0p7efzlwybl4Bcs5mhg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>211380900</pqid></control><display><type>article</type><title>Adamantane Resistance Among Influenza A Viruses Isolated Early During the 2005-2006 Influenza Season in the United States</title><source>MEDLINE</source><source>American Medical Association Journals</source><creator>Bright, Rick A ; Shay, David K ; Shu, Bo ; Cox, Nancy J ; Klimov, Alexander I</creator><creatorcontrib>Bright, Rick A ; Shay, David K ; Shu, Bo ; Cox, Nancy J ; Klimov, Alexander I</creatorcontrib><description>CONTEXT The adamantanes, amantadine and rimantadine, have been used as first-choice
antiviral drugs against community outbreaks of influenza A viruses for many
years. Rates of viruses resistant to these drugs have been increasing globally.
Rapid surveillance for the emergence and spread of resistant viruses has become
critical for appropriate treatment of patients. OBJECTIVE To investigate the frequency of adamantane-resistant influenza A viruses
circulating in the United States during the initial months of the 2005-2006
influenza season. DESIGN AND SETTING Influenza isolates collected from 26 states from October 1 through December
31, 2005, and submitted to the US Centers for Disease Control and Prevention
were tested for drug resistance as part of ongoing surveillance. Isolates
were submitted from World Health Organization collaborating laboratories and
National Respiratory and Enteric Virus Surveillance System laboratories. MAIN OUTCOME MEASURES Using pyrosequencing and confirmatory assays, we identified viruses
containing mutations within the M2 gene that are known to confer resistance
to both amantadine and rimantadine. RESULTS A total of 209 influenza A(H3N2) viruses isolated from patients in 26
states were screened, of which 193 (92.3%) contained a change at amino acid
31 (serine to asparagine [S31N]) in the M2 gene known to be correlated with
adamantane resistance. Two of 8 influenza A(H1N1) viruses contained the same
mutation. Drug-resistant viruses were distributed across the United States. CONCLUSIONS The high proportion of influenza A viruses currently circulating in
the United States demonstrating adamantane resistance highlights the clinical
importance of rapid surveillance for antiviral resistance. Our results indicate
that these drugs should not be used for the treatment or prophylaxis of influenza
in the United States until susceptibility to adamantanes has been reestablished
among circulating influenza A isolates.Published online February 2, 2006 (doi:10.1001/jama.295.8.joc60020).</description><identifier>ISSN: 0098-7484</identifier><identifier>EISSN: 1538-3598</identifier><identifier>DOI: 10.1001/jama.295.8.joc60020</identifier><identifier>PMID: 16456087</identifier><identifier>CODEN: JAMAAP</identifier><language>eng</language><publisher>Chicago, IL: American Medical Association</publisher><subject>Adamantane - pharmacology ; Antiviral Agents - pharmacology ; Biological and medical sciences ; Biological Assay ; Data analysis ; Disease control ; Drug resistance ; Drug Resistance, Viral - genetics ; General aspects ; Humans ; Infectious diseases ; Influenza ; Influenza A virus - drug effects ; Influenza A virus - genetics ; Influenza A Virus, H1N1 Subtype - drug effects ; Influenza A Virus, H1N1 Subtype - genetics ; Influenza A Virus, H3N2 Subtype - drug effects ; Influenza A Virus, H3N2 Subtype - genetics ; Influenza virus ; Influenza, Human - drug therapy ; Medical sciences ; Miscellaneous ; Mutation ; Public health. Hygiene ; Public health. Hygiene-occupational medicine ; Seasons ; Sequence Analysis ; United States ; Viral Matrix Proteins - genetics ; Viruses</subject><ispartof>JAMA : the journal of the American Medical Association, 2006-02, Vol.295 (8), p.891-894</ispartof><rights>2006 INIST-CNRS</rights><rights>Copyright American Medical Association Feb 22, 2006</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a410t-78954027102cfa35b1e71bc94d44ea7c1ffb42877ee6cb48f36456ff4e75513c3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://jamanetwork.com/journals/jama/articlepdf/10.1001/jama.295.8.joc60020$$EPDF$$P50$$Gama$$H</linktopdf><linktohtml>$$Uhttps://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.295.8.joc60020$$EHTML$$P50$$Gama$$H</linktohtml><link.rule.ids>64,314,776,780,3327,27901,27902,76232,76235</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17501203$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16456087$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bright, Rick A</creatorcontrib><creatorcontrib>Shay, David K</creatorcontrib><creatorcontrib>Shu, Bo</creatorcontrib><creatorcontrib>Cox, Nancy J</creatorcontrib><creatorcontrib>Klimov, Alexander I</creatorcontrib><title>Adamantane Resistance Among Influenza A Viruses Isolated Early During the 2005-2006 Influenza Season in the United States</title><title>JAMA : the journal of the American Medical Association</title><addtitle>JAMA</addtitle><description>CONTEXT The adamantanes, amantadine and rimantadine, have been used as first-choice
antiviral drugs against community outbreaks of influenza A viruses for many
years. Rates of viruses resistant to these drugs have been increasing globally.
Rapid surveillance for the emergence and spread of resistant viruses has become
critical for appropriate treatment of patients. OBJECTIVE To investigate the frequency of adamantane-resistant influenza A viruses
circulating in the United States during the initial months of the 2005-2006
influenza season. DESIGN AND SETTING Influenza isolates collected from 26 states from October 1 through December
31, 2005, and submitted to the US Centers for Disease Control and Prevention
were tested for drug resistance as part of ongoing surveillance. Isolates
were submitted from World Health Organization collaborating laboratories and
National Respiratory and Enteric Virus Surveillance System laboratories. MAIN OUTCOME MEASURES Using pyrosequencing and confirmatory assays, we identified viruses
containing mutations within the M2 gene that are known to confer resistance
to both amantadine and rimantadine. RESULTS A total of 209 influenza A(H3N2) viruses isolated from patients in 26
states were screened, of which 193 (92.3%) contained a change at amino acid
31 (serine to asparagine [S31N]) in the M2 gene known to be correlated with
adamantane resistance. Two of 8 influenza A(H1N1) viruses contained the same
mutation. Drug-resistant viruses were distributed across the United States. CONCLUSIONS The high proportion of influenza A viruses currently circulating in
the United States demonstrating adamantane resistance highlights the clinical
importance of rapid surveillance for antiviral resistance. Our results indicate
that these drugs should not be used for the treatment or prophylaxis of influenza
in the United States until susceptibility to adamantanes has been reestablished
among circulating influenza A isolates.Published online February 2, 2006 (doi:10.1001/jama.295.8.joc60020).</description><subject>Adamantane - pharmacology</subject><subject>Antiviral Agents - pharmacology</subject><subject>Biological and medical sciences</subject><subject>Biological Assay</subject><subject>Data analysis</subject><subject>Disease control</subject><subject>Drug resistance</subject><subject>Drug Resistance, Viral - genetics</subject><subject>General aspects</subject><subject>Humans</subject><subject>Infectious diseases</subject><subject>Influenza</subject><subject>Influenza A virus - drug effects</subject><subject>Influenza A virus - genetics</subject><subject>Influenza A Virus, H1N1 Subtype - drug effects</subject><subject>Influenza A Virus, H1N1 Subtype - genetics</subject><subject>Influenza A Virus, H3N2 Subtype - drug effects</subject><subject>Influenza A Virus, H3N2 Subtype - genetics</subject><subject>Influenza virus</subject><subject>Influenza, Human - drug therapy</subject><subject>Medical sciences</subject><subject>Miscellaneous</subject><subject>Mutation</subject><subject>Public health. Hygiene</subject><subject>Public health. Hygiene-occupational medicine</subject><subject>Seasons</subject><subject>Sequence Analysis</subject><subject>United States</subject><subject>Viral Matrix Proteins - genetics</subject><subject>Viruses</subject><issn>0098-7484</issn><issn>1538-3598</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkVtr3DAQhUVIaDaXH1AKQRTSN29GN0t-XNKkWQgEcns1snbUerHlxLIfNr8-2uw2LXmJHkYCfXOGc4aQbwymDICdLW1rp7xQUzNddi4H4LBDJkwJkwlVmF0yAShMpqWR--QgxiWkw4T-QvZZLlUORk_IarZIMmGwAektxjqml0M6a7vwm86Db0YML5bO6GPdjxEjnceusQMu6IXtmxX9OfZ1Ioc_SDmAylLJ_-u7Qxu7QOvwRjyEet15NySBeET2vG0iHm_vQ_JweXF_fpVd3_yan8-uMysZDJk2hZLANQPuvBWqYqhZ5Qq5kBKtdsz7SnKjNWLuKmm8WHvzXqJWigknDsmPje5T3z2PGIeyraPDpkmWuzGWuc5NLgv4FGQ6JcZBJPD7B3DZjX1IJkrOmDBQwFrtZAuNVYuL8qmvW9uvyr_RJ-B0C9jobOP7FHwd_3FaAdtM-7rh0p7efzlwybl4Bcs5mhg</recordid><startdate>20060222</startdate><enddate>20060222</enddate><creator>Bright, Rick A</creator><creator>Shay, David K</creator><creator>Shu, Bo</creator><creator>Cox, Nancy J</creator><creator>Klimov, Alexander I</creator><general>American Medical Association</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7QL</scope><scope>7QP</scope><scope>7TK</scope><scope>7TS</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>20060222</creationdate><title>Adamantane Resistance Among Influenza A Viruses Isolated Early During the 2005-2006 Influenza Season in the United States</title><author>Bright, Rick A ; Shay, David K ; Shu, Bo ; Cox, Nancy J ; Klimov, Alexander I</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a410t-78954027102cfa35b1e71bc94d44ea7c1ffb42877ee6cb48f36456ff4e75513c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Adamantane - pharmacology</topic><topic>Antiviral Agents - pharmacology</topic><topic>Biological and medical sciences</topic><topic>Biological Assay</topic><topic>Data analysis</topic><topic>Disease control</topic><topic>Drug resistance</topic><topic>Drug Resistance, Viral - genetics</topic><topic>General aspects</topic><topic>Humans</topic><topic>Infectious diseases</topic><topic>Influenza</topic><topic>Influenza A virus - drug effects</topic><topic>Influenza A virus - genetics</topic><topic>Influenza A Virus, H1N1 Subtype - drug effects</topic><topic>Influenza A Virus, H1N1 Subtype - genetics</topic><topic>Influenza A Virus, H3N2 Subtype - drug effects</topic><topic>Influenza A Virus, H3N2 Subtype - genetics</topic><topic>Influenza virus</topic><topic>Influenza, Human - drug therapy</topic><topic>Medical sciences</topic><topic>Miscellaneous</topic><topic>Mutation</topic><topic>Public health. Hygiene</topic><topic>Public health. Hygiene-occupational medicine</topic><topic>Seasons</topic><topic>Sequence Analysis</topic><topic>United States</topic><topic>Viral Matrix Proteins - genetics</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bright, Rick A</creatorcontrib><creatorcontrib>Shay, David K</creatorcontrib><creatorcontrib>Shu, Bo</creatorcontrib><creatorcontrib>Cox, Nancy J</creatorcontrib><creatorcontrib>Klimov, Alexander I</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Physical Education Index</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>JAMA : the journal of the American Medical Association</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bright, Rick A</au><au>Shay, David K</au><au>Shu, Bo</au><au>Cox, Nancy J</au><au>Klimov, Alexander I</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Adamantane Resistance Among Influenza A Viruses Isolated Early During the 2005-2006 Influenza Season in the United States</atitle><jtitle>JAMA : the journal of the American Medical Association</jtitle><addtitle>JAMA</addtitle><date>2006-02-22</date><risdate>2006</risdate><volume>295</volume><issue>8</issue><spage>891</spage><epage>894</epage><pages>891-894</pages><issn>0098-7484</issn><eissn>1538-3598</eissn><coden>JAMAAP</coden><abstract>CONTEXT The adamantanes, amantadine and rimantadine, have been used as first-choice
antiviral drugs against community outbreaks of influenza A viruses for many
years. Rates of viruses resistant to these drugs have been increasing globally.
Rapid surveillance for the emergence and spread of resistant viruses has become
critical for appropriate treatment of patients. OBJECTIVE To investigate the frequency of adamantane-resistant influenza A viruses
circulating in the United States during the initial months of the 2005-2006
influenza season. DESIGN AND SETTING Influenza isolates collected from 26 states from October 1 through December
31, 2005, and submitted to the US Centers for Disease Control and Prevention
were tested for drug resistance as part of ongoing surveillance. Isolates
were submitted from World Health Organization collaborating laboratories and
National Respiratory and Enteric Virus Surveillance System laboratories. MAIN OUTCOME MEASURES Using pyrosequencing and confirmatory assays, we identified viruses
containing mutations within the M2 gene that are known to confer resistance
to both amantadine and rimantadine. RESULTS A total of 209 influenza A(H3N2) viruses isolated from patients in 26
states were screened, of which 193 (92.3%) contained a change at amino acid
31 (serine to asparagine [S31N]) in the M2 gene known to be correlated with
adamantane resistance. Two of 8 influenza A(H1N1) viruses contained the same
mutation. Drug-resistant viruses were distributed across the United States. CONCLUSIONS The high proportion of influenza A viruses currently circulating in
the United States demonstrating adamantane resistance highlights the clinical
importance of rapid surveillance for antiviral resistance. Our results indicate
that these drugs should not be used for the treatment or prophylaxis of influenza
in the United States until susceptibility to adamantanes has been reestablished
among circulating influenza A isolates.Published online February 2, 2006 (doi:10.1001/jama.295.8.joc60020).</abstract><cop>Chicago, IL</cop><pub>American Medical Association</pub><pmid>16456087</pmid><doi>10.1001/jama.295.8.joc60020</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0098-7484 |
| ispartof | JAMA : the journal of the American Medical Association, 2006-02, Vol.295 (8), p.891-894 |
| issn | 0098-7484 1538-3598 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67686490 |
| source | MEDLINE; American Medical Association Journals |
| subjects | Adamantane - pharmacology Antiviral Agents - pharmacology Biological and medical sciences Biological Assay Data analysis Disease control Drug resistance Drug Resistance, Viral - genetics General aspects Humans Infectious diseases Influenza Influenza A virus - drug effects Influenza A virus - genetics Influenza A Virus, H1N1 Subtype - drug effects Influenza A Virus, H1N1 Subtype - genetics Influenza A Virus, H3N2 Subtype - drug effects Influenza A Virus, H3N2 Subtype - genetics Influenza virus Influenza, Human - drug therapy Medical sciences Miscellaneous Mutation Public health. Hygiene Public health. Hygiene-occupational medicine Seasons Sequence Analysis United States Viral Matrix Proteins - genetics Viruses |
| title | Adamantane Resistance Among Influenza A Viruses Isolated Early During the 2005-2006 Influenza Season in the United States |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T12%3A53%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Adamantane%20Resistance%20Among%20Influenza%20A%20Viruses%20Isolated%20Early%20During%20the%202005-2006%20Influenza%20Season%20in%20the%20United%20States&rft.jtitle=JAMA%20:%20the%20journal%20of%20the%20American%20Medical%20Association&rft.au=Bright,%20Rick%20A&rft.date=2006-02-22&rft.volume=295&rft.issue=8&rft.spage=891&rft.epage=894&rft.pages=891-894&rft.issn=0098-7484&rft.eissn=1538-3598&rft.coden=JAMAAP&rft_id=info:doi/10.1001/jama.295.8.joc60020&rft_dat=%3Cproquest_pubme%3E994463541%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=211380900&rft_id=info:pmid/16456087&rft_ama_id=202422&rfr_iscdi=true |